Post
Relmada reports data from trial of REL-1017 for major depressive disorder
The RELIANCE I trial results showed that REL-1017-treated patients had a 15.1 point reduction in the MADRS.
Sitero and CRIO partner to improve patient safety in trials
The collaboration will remove the need for redundant, manual, and error-prone activities across the clinical lifecycle.
Suvoda unveils electronic clinical outcome assessments design toolkit
The toolkit is created to integrate with the Suvoda IRT and eConsent, and also address the historical inadequacies that impact eCOA.
Next on diversity: inclusion of participants with cognitive impairment in clinical trials
Clinical Trials Arena dives into a frequently forgotten aspect of clinical trial diversity: participation of people with cognitive disabilities.
China NMPA grants IND clearance for trial of Ascletis’ Covid-19 drug
ASC11 was found to have potent antiviral activity against BA.1 and BA.5 Omicron variants.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Neurocrine therapy fails to meet endpoint in epileptic encephalopathy trial
The trial evaluated NBI-827104 when given once a day up to 13 weeks in paediatric EE-CSWS patients.
Tetra Bio-Pharma reports results from trial of ARDS-003 and Favipiravir
Onternabez plays a key role in mitigating the inflammatory response in various inflammatory condition targets.
Alzheimer’s disease drug development: three major questions for 2023
After a chaotic 2022 that saw both drug development successes and failures, the Alzheimer’s disease field faces questions over upcoming data and new therapeutic approaches.
Medidata unveils new app to accelerate start up of trial
The app is integrated with the Medidata Platform, including the Rave EDC, to offer a self-sustaining ecosystem.
US FDA grants clearance to commence trials of Sorrento’s mRNA vaccine
The microneedle system, along with an mRNA vaccine candidate, showed enhanced humoral immunity in animal models.
BioAge Labs reports positive data from muscle atrophy treatment trial
Findings showed that BGE-105 resulted in statistically significant improvements in muscle size, quality, and protein synthesis.
Longboard reports positive data from Phase I LP352 clinical study
The trial findings showed that LP352 exhibited a strong correlation between plasma and CSF PK concentration.
Mirati reports initial data from lung cancer trials
Grade 1-2, Grade 3, and Grade 4 treatment-related adverse events were reported in the trial.
Novartis’ Phase III prostate cancer therapy trial meets primary endpoint
Assessing overall survival, which is the crucial secondary endpoint of the trial, is progressing.